Lonza Group AG: Business Overview, Financials & Competitive Analysis
Lonza Group AG scores 8/10 on the AskCyborg Cyborg Score (Strong). Diversified CDMO leader with strong profitability expansion, well-positioned for sustained double-digit growth in 2026. Lonza reported strong 2025 revenue growth of 17.3% (constant exchange rate), beating consensus, with core EBITDA margin of 30.6% outperforming expectations. For 2026, the company forecast 11-12% constant exchange rate sales growth and core EBITDA.
What is Lonza Group AG's industry? Lonza Group AG (lonza.com) operates in Contract Development and Manufacturing Organization (CDMO) / Pharmaceutical Manufacturing Services. AskCyborg classifies Lonza Group AG under Contract Development and Manufacturing Organization (CDMO) / Pharmaceutical Manufacturing Services in its company registry.
Lonza is a contract development and manufacturing organization operating across four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. The company provides development and manuf...
Cyborg Score thesis
Diversified CDMO leader with strong profitability expansion, well-positioned for sustained double-digit growth in...
Read the full analyst-debate transcript →Get the Latest Lonza Group AG Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeLonza Group AG Overview
Pro stress-test →Lonza is a contract development and manufacturing organization operating across four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply.
Strategic Profile
Pro stress-test →Lonza's business model has proven resilient, effectively diversifying risks across the broadest technology offering, commercial portfolio and global manufacturing footprint in the CDMO industry. The strong economic rationale to outsource to CDMOs remains unchanged for large pharma and biotech companies to enable economically efficient global pharmaceutical supply.
Competitive Landscape
Pro stress-test →Key competitors include Siegfried Holding, KBI BioPharma, Patheon, CordenPharma, and Vetter Pharma. Lonza maintains competitive advantage through its diversified technology platform, extensive manufacturing footprint, and strong customer relationships with large pharmaceutical and biotech companies.
Industry Context
Lonza Group AG operates in Contract Development and Manufacturing Organization (CDMO) / Pharmaceutical Manufacturing Services.
Key facts
Founded: 1897 · Headquarters: Basel, Switzerland · Revenue: $8.17B · Market cap: $49.6B